Evidence map›Paper›PMID 31912273›Full record

ArticleClinical and experimental nephrology2020

Hexapeptide derived from prothymosin alpha attenuates cisplatin-induced acute kidney injury.

Kenta Torigoe, Yoko Obata, Miki Torigoe, Satoru Oka, Kazuo Yamamoto, Takehiko Koji, Hiroshi Ueda, Hiroshi Mukae, Tomoya Nishino

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kenta TorigoeDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Yoko ObataDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. yobata-ngs@umin.ac.jp.
Miki TorigoeDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Satoru OkaDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Kazuo YamamotoBiomedical Research Support Center, Nagasaki University School of Medicine, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Takehiko KojiDepartment of Histology and Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Hiroshi UedaDepartment of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki, 852-8521, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Tomoya NishinoDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Nagasaki University · JPNagasaki University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProthymosin alpha (ProTα) is a nuclear protein expressed in virtually all mammalian tissues. Previous studies have shown that ProTα exhibits protective effects against ischemia-induced cell death in various cell types. Recently, the 6-residue peptide P

methodsCultured HK-2 cells were treated with cisplatin for 24 h and pretreatment with ProTα or P

resultsIn the study on cultured cells, pretreatment with ProTα or P

conclusionTaken together, our findings indicate that P

Indexed as

Acute Kidney InjuryAnimalsAntineoplastic AgentsApoptosisBlood Urea NitrogenCell LineCell SurvivalCisplatinCreatinineHumansKidney Tubules, ProximalMaleMitochondriaPeptidesPhosphorylationProto-Oncogene Proteins c-aktAntineoplastic AgentsCisplatinCreatininePeptidesProto-Oncogene Proteins c-aktAcute kidney injuryApoptosisCisplatin nephrotoxicityProthymosin alphaRenoprotective peptide

Identifiers

PMID31912273
OpenAlexW2999518921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.